NIH VideoCast - Comparison of Immunogenicity and Vaccine Effectiveness of Inactivated and RNA COVID-19 Vaccines

Skip Navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Comparison of Immunogenicity and Vaccine Effectiveness of Inactivated and RNA COVID-19 Vaccines

Loading... Loading video...

310 Views

Air date:	Thursday, May 4, 2023, 12:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 310 (206 Live, 104 On-demand)
Category:	COVID-19
Runtime:	00:47:56
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	In 2003, Professor Peiris and his research team discovered SARS-CoV, a novel coronavirus, as the etiological agent for SARS. He joined The University of Hong Kong in 1995, and is now Chair of Virology at the School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China. He co-directs the WHO H5 Reference Laboratory and the WHO SARS-CoV-2 reference laboratory at The University of Hong Kong. Currently, he serves on many Hong Kong and WHO advisory committees, including the WHO International Health Regulations Emergency Committee on COVID-19. He is a clinical and public health virologist with a particular interest in emerging viral diseases at the animal-human interface – using a “One-Health” approach. His research encompasses the pathogenesis, innate immune responses, transmission, ecology and epidemiology of human and animal influenza viruses such as avian influenza subtypes H5N1, H9N2 and H7N9, the emergence of the 2009 pandemic H1N1 from swine, and coronaviruses such as SARS-CoV-1, MERS-CoV, and SARS-CoV-2.

NLM Title:	Comparison of immunogenicity and vaccine effectiveness of inactivated and RNA COVID-19 vaccines / Joseph Sriyal Malik Peiris.
Author:	Peiris, Malik. National Institutes of Health (U.S.). COVID-19 Scientific Interest Group,
Publisher:
Abstract:	(CIT): In 2003, Professor Peiris and his research team discovered SARS-CoV, a novel coronavirus, as the etiological agent for SARS. He joined The University of Hong Kong in 1995, and is now Chair of Virology at the School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China. He co-directs the WHO H5 Reference Laboratory and the WHO SARS-CoV-2 reference laboratory at The University of Hong Kong. Currently, he serves on many Hong Kong and WHO advisory committees, including the WHO International Health Regulations Emergency Committee on COVID-19. He is a clinical and public health virologist with a particular interest in emerging viral diseases at the animal-human interface - using a "One-Health" approach. His research encompasses the pathogenesis, innate immune responses, transmission, ecology and epidemiology of human and animal influenza viruses such as avian influenza subtypes H5N1, H9N2 and H7N9, the emergence of the 2009 pandemic H1N1 from swine, and coronaviruses such as SARS-CoV-1, MERS-CoV, and SARS-CoV-2.
Subjects:	2019-nCoV Vaccine mRNA-1273--immunology COVID-19--immunology COVID-19--prevention & control Immunogenicity, Vaccine Treatment Outcome Vaccines, Inactivated
Publication Types:	Lecture Webcast

NLM Classification:	WC 506.6
NLM ID:	9918625745706676
CIT Live ID:	49177
Permanent link:	https://videocast.nih.gov/watch=49177

Related Videos...